WO2014201618A1 - Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables - Google Patents

Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables Download PDF

Info

Publication number
WO2014201618A1
WO2014201618A1 PCT/CN2013/077374 CN2013077374W WO2014201618A1 WO 2014201618 A1 WO2014201618 A1 WO 2014201618A1 CN 2013077374 W CN2013077374 W CN 2013077374W WO 2014201618 A1 WO2014201618 A1 WO 2014201618A1
Authority
WO
WIPO (PCT)
Prior art keywords
injection
cosmetic product
xanthan gum
isotonic
buffer
Prior art date
Application number
PCT/CN2013/077374
Other languages
English (en)
Chinese (zh)
Inventor
凌沛学
韩冠英
王桂兰
宋志刚
邵华荣
朱希强
刘飞
颜震
窦茜茜
侯重文
Original Assignee
山东省生物药物研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 山东省生物药物研究院 filed Critical 山东省生物药物研究院
Priority to CN201380077303.7A priority Critical patent/CN105338988B/zh
Priority to PCT/CN2013/077374 priority patent/WO2014201618A1/fr
Publication of WO2014201618A1 publication Critical patent/WO2014201618A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/723—Xanthans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Definitions

  • the invention belongs to the technical field of medicine, and relates to the use of xanthan gum in preparing an injection cosmetic product and an injection cosmetic product containing xanthan gum. Background technique
  • Injection beauty refers to a method of injecting a specific bio-filling material or preparation into a target site that needs to be repaired and remodeled according to different injection routes to achieve a young and beautiful natural beauty.
  • the injection beauty operation is simple, the damage is small, and the recovery is fast.
  • dermal fillers have been approved by the US FDA as a medical device to fill facial wrinkles. These products can be used to inject deep or deep dermis to repair moderate or deep skin wrinkles, wrinkles or scars. It is widely used in clinical practice to eliminate wrinkles, lip augmentation, rhinoplasty, chin chin, brocade and various dent fillings.
  • Non-biological dermal fillers are not biodegradable and have permanent filling properties, mainly including silica gel, polymethyl methacrylate, polyacrylamide, hydroxyphosphorus ⁇ , etc., which remain in the body for a long time and cannot be completely removed. The reaction rate is higher and less used for facial skin filling.
  • Biomaterials are biodegradable, with short durations, some only a few months, but the incidence of adverse events is low, relative to ⁇ . It mainly includes products such as protein, hyaluronic acid, and autologous cells. ⁇ Protein products are divided into human and non-human sources.
  • Non-human sources are human heterologous proteins, which are prone to occur. Rejection, resulting in excessive and complications. Autologous cell products take more autologous tissue cells, the patient suffers, and the cell proliferation is slow, and it is effective after a long time after injection, and multiple injections are required. At present, there are many hyaluronic acid fillers. Hyaluronic acid is a substance existing in the human body. It has good histocompatibility, no allergic reaction, and non-heating. Source, not carcinogenic, causing (Falcone SJ, Doerfler AM, Berg R A. Dermal Fillers: Types, Indications, and Complications. Dermatol Surg, 2007,
  • Xanthan gum is a black rot of Xanthomonas ⁇ Xanthomonas
  • the basic structure is composed of repeating pentasaccharide units, this unit consists of two D- glucose, D- mannose, and two 1 D-glucuronic acid composition.
  • the primary structure of the xanthan gum molecule consists of a D-glucose backbone linked to a ?-1,4 bond and a side chain of a trisaccharide unit, the side chains of which are alternately linked by D-mannose and D-glucuronic acid.
  • the mannose at the end of the partial side chain is linked to a pyruvate group at the 4th and 6th positions, while the mannose partially linked to the main chain is acetylated at the C-6 position;
  • the secondary structure is the side chain through the hydrogen bond
  • a tertiary structure is a network structure in which a secondary structure is composed of non-covalent bonds.
  • xanthan gum is widely used in food, medicine, cosmetics, petroleum, textile and papermaking (Garcia-Ochoa F, Santos VE, Casas JA, et al. Xanthan gum: production, recovery, and properties. Biotechnol Adv, 2000, 18(7): 549-579). However, no reports of xanthan gum for the preparation of cosmetic products have been reported. Summary of the invention
  • the inventors of the present invention have surprisingly found that xanthan gum can be used in a large number of experiments.
  • the present invention has been completed by preparing a cosmetic product, particularly an injection cosmetic product which can be used for preparing wrinkles, fine lines, epidermal depressions and/or scars.
  • a first aspect of the invention relates to the use of xanthan gum in the preparation of an injection cosmetic product filled with wrinkles, fine lines, epidermal depressions and/or scars.
  • the content of xanthan gum in the injection cosmetic product is from 0.25 w/v% to 10 w/v%, preferably, the content of the xanthan gum is 0.5 w/v% ⁇ 8.0 w/v%, more preferably, the xanthan gum is 0.5 w/v% to 5 w/v%, for example, 1 w/v% to 5 w/v%, 2 w/v% ⁇ 5 w/v%.
  • the xanthan gum has an average relative molecular mass of from 2 to 20 million, preferably from 3 to 10 million.
  • the injection cosmetic product has a viscosity of from 100 to 2000 Pa s, preferably from 300 to 1000 Pa's.
  • the degree can be measured by methods well known in the art.
  • the degree data is determined using a rotational rheometer (Malvern Kinexus, Germany) at a shear rate of 0.1 s" 1 .
  • the injection cosmetic product has a pH of 5.5 to 8.5, preferably a pH of 6.0 to 8.0, more preferably a pH of 7.0 to 7.4.
  • the injection cosmetic product is a liquid preparation or formulation.
  • the content of xanthan gum in the product is low ( ⁇ 2%), it is a liquid state with good fluidity.
  • the product is a liquid preparation; as the concentration of xanthan gum in the product increases, the viscosity of the solution increases, and the fluidity deteriorates. , to become a viscous gel state, the product at this time can be regarded as a gel preparation.
  • the injection cosmetic product further comprises a biocompatible solvent, and optionally other physiologically acceptable raw and auxiliary ingredients.
  • the biocompatible solvent is a sterile, pyrogen-free, isotonic aqueous solution
  • the sterile, non-pyrogenic, isotonic aqueous solution is selected from the group consisting of sterile, non-pyrogenic physiological saline, Isotonic glucose solution, isotonic borate buffer, isotonic phosphate buffer, isotonic citrate buffer, isotonic tartrate buffer, isotonic lactate buffer, etc.
  • osmium carbonate buffer and isotonic acetate buffer for example, two or three Kind
  • the isotate buffer ⁇ ! An isotonic buffer system consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium chloride; the isotonic borate buffer is an isotonic buffer system consisting of boric acid, borax, and sodium chloride.
  • the raw material component is selected from one or both of a glycan and a local anesthetic; preferably, the hyaluronic acid, chondroitin sulfate, and quercetin sulfate Or one or more of heparan sulfate, keratan sulfate, heparin, wherein the content of the glycan in the injection cosmetic product is 0.125 w/v% to 10 w/v%, preferably, the poly
  • the sugar is from 0.25 w/v% to 5.0 w/v%, more preferably, the glycan is from 0.5 w/v% to 3.0 w/v%, from 0.5 w/v% to 1.0 w/v% or lw. /v% ⁇ 3 w/v%.
  • the local anesthetic is selected from one or more of lidocaine, procaine, bupivacaine, tetracaine, ropivacaine, and salts thereof.
  • the amount of the local anesthetic is the usual dosage in the art, for example, the concentration is about 0.1 w/v% to about 5.0 w/v% of the injection cosmetic product.
  • the injection cosmetic product is for intradermal injection or subcutaneous injection.
  • a second aspect of the invention relates to an injection cosmetic product for filling wrinkles, fine lines, epidermal depressions and/or scars, wherein the injection cosmetic product contains xanthan gum.
  • An injection cosmetic product wherein the content of xanthan gum in the injection cosmetic product is from 0.25 w/v% to 10 w/v%, preferably, the content of the xanthan gum is 0.5 w/ v% ⁇ 8.0 w/v%, more preferably, the x-ray of the xanthan gum is 0.5 w/v% ⁇ 5 w/v%, for example, 1 w/v% ⁇ 5 w/v%, 2 w/v% ⁇ 5 w/v%.
  • the injection cosmetic product according to the second aspect of the invention wherein the xanthan gum has an average molecular weight of from 2 to 20 million, preferably from 3 to 10,000,000.
  • an injection cosmetic product according to the second aspect of the invention wherein the injection cosmetic product has a viscosity of from 100 to 2000 Pa s, preferably from 300 to 1000 Pa's.
  • a viscosity of from 100 to 2000 Pa s, preferably from 300 to 1000 Pa's.
  • the viscosity data is using a rotational rheometer
  • An injection cosmetic product according to a second aspect of the invention wherein the injection cosmetic product has a pH of 5.5 to 8.5, preferably, a pH of 6.0 to 8.0, more preferably a pH of 7.0 to 2 according to the second aspect of the invention
  • An injection cosmetic product, wherein the injection cosmetic product is a liquid preparation or a gel preparation.
  • an injection cosmetic product according to the second aspect of the invention wherein the injection cosmetic product further comprises a biocompatible solvent, and optionally other physiologically acceptable raw and auxiliary ingredients.
  • biocompatible solvent is a sterile, pyrogen-free, isotonic aqueous solution
  • the sterile, non-pyrogenic, isotonic aqueous solution is selected from the group consisting of a sterile, non-pyrogenic physiology Saline, isotonic glucose solution, isotonic borate buffer, isotonic phosphate buffer, isotonic citrate buffer, isotonic tartrate buffer, isotonic lactate buffer
  • One or more of isotonic carbonate buffer and isotonic acetate buffer isotonic acetate buffer.
  • the isotate buffer ⁇ ! An isotonic buffer system consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium chloride; the isotonic borate buffer is an isotonic buffer system consisting of boric acid, borax, and sodium chloride.
  • an injection cosmetic product wherein the prosthetic material is one or two selected from the group consisting of amino glycans and local anesthetics; preferably, the amino polysaccharide is selected from the group consisting of hyaluronic acid and sulfuric acid.
  • chondroitin, quercetin sulfate, heparan sulfate, keratan sulfate, heparin wherein the content of the aminoglycan in the injection cosmetic product is 0.125 w/v% to 10 w/v%
  • the content is from 0.25 w/v% to 5.0 w/v%
  • the glycan is from 0.5 w/v% to 3.0 w/v%, 0.5 w/v% to 1.0. w/v% ⁇ 1 w/v% ⁇ 3 w/v%.
  • the anesthetic is selected from one or more of lidocaine, procaine, bupivacaine, tetracaine, ropivacaine, and salts thereof.
  • the amount of the local anesthetic is conventionally used in the art, for example, at a concentration of from about 0.1 w/v% to about 5.0 w/v% of the injection cosmetic product.
  • An injection cosmetic product according to the second aspect of the invention the injection cosmetic product for intradermal administration Injection or subcutaneous injection.
  • a third aspect of the invention relates to the use of the injection cosmetic product according to any one of the second aspects of the invention for the preparation of a cosmetic injection for filling wrinkles, fine lines, epidermal depressions and/or scars.
  • a fourth aspect of the invention relates to a cosmetic method for filling wrinkles, fine lines, epidermal depressions and/or scars, the method comprising the step of injecting a cosmetic product containing xanthan gum; preferably, the cosmetic product containing xanthan gum is The invention relates to an injection cosmetic product according to any of the second aspects of the invention.
  • a cosmetic method wherein the content of xanthan gum in the cosmetic product is from 0.25 w/v% to 10 w/v%, preferably, the content of the xanthan gum is 0.5 w/v% ⁇ 8.0 w/v%, more preferably, the xanthan gum is 0.5 w/v% to 5 w/v%, for example, 1 w/v% to 5 w/v%, 2 w/v% ⁇ 5 w/v%.
  • the cosmetic method according to the fourth aspect of the present invention wherein the xanthan gum has an average relative molecular mass of 2 to 20,000,000, preferably 3 to 10,000,000.
  • the cosmetic method according to the fourth aspect of the invention wherein the injection cosmetic product has a viscosity of 100 to 2000 Pa s, preferably 300 to 1000 Pa's.
  • the degree can be measured by methods well known in the art.
  • the degree data is determined using a rotational rheometer (Malvern Kinexus, Germany) at a shear rate of 0.1 s" 1 .
  • the cosmetic method according to the fourth aspect of the present invention wherein the injection cosmetic product has a pH of from 5. 5 to 8. 5, preferably, a pH of from 6.8 to 8.0, more preferably, a pH of 7 ⁇ 0 ⁇ 7.4.
  • a cosmetic method according to the fourth aspect of the invention wherein the injection cosmetic product is a liquid preparation or a gel preparation.
  • the injection cosmetic product further comprises a biocompatible solvent, and optionally other physiologically acceptable raw and auxiliary ingredients.
  • the biocompatible solvent is a sterile, pyrogen-free, isotonic aqueous solution
  • the sterile, non-pyrogenic, isotonic aqueous solution is selected from the group consisting of sterile, non-pyrogenic physiological saline.
  • Isotonic glucose solution, isotonic borate buffer, isotonic phosphate Buffer, isotonic citrate buffer, isotonic tartrate buffer, isotonic lactate buffer, isotonic carbonate buffer and isotonic acetate buffer One or several.
  • the isotate buffer ⁇ ! An isotonic buffer system consisting of disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium chloride; the isotonic borate buffer is an isotonic buffer system consisting of boric acid, borax, and sodium chloride.
  • the raw material component is one or more selected from the group consisting of a glycan and a local anesthetic; preferably, the amino polysaccharide is selected from the group consisting of hyaluronic acid and chondroitin sulfate Or one or more of quercetin sulfate, heparan sulfate, keratan sulfate, heparin, wherein the content of the polysaccharide in the injection cosmetic product is 0.125 w/v% to 10 w/v%, preferably The glycan is 0.25 w/v% to 5.0 w/v%, and more preferably, the glycan is 0.5 w/v% to 3.0 w/v%, 0.5 w/v% to 1.0 w.
  • the anesthetic is selected from one or more of lidocaine, procaine, bupivacaine, tetracaine, ropivacaine, and salts thereof.
  • the amount of the local anesthetic is conventionally used in the art, for example, at a concentration of from about 0.1 w/v% to about 5.0 w/v% of the injected cosmetic product.
  • the injection cosmetic product is used for intradermal injection or subcutaneous injection.
  • the xanthan gum is produced by fermentation of Xanthomonas oryzae, and the molecular weight of xanthan gum is determined by a multi-angle laser 3 ⁇ 4 (Wyatt Technology, DAWN EOS) combined with 'permeation chromatography. Under the same conditions, the viscosity of the xanthan gum solution increases with the increase of its molecular weight.
  • the wrinkles, fine lines, skin depressions and scars respectively mean that the embossed lines formed by the human skin due to aging or being affected by the external environment are called wrinkles.
  • Fine lines are a kind of wrinkles.
  • the linear aging of human muscles and the long-term contraction of eye muscles are called fine lines.
  • Epidermal depression refers to a narrow surface depression or a depressed scar formed by a series of physiological or pathological factors, which are caused by defects in the dermis and subcutaneous tissues of the skin. Scars are external to normal skin and narrow tissue caused by various traumas
  • the cosmetic product includes a medicine, a preparation, and the like for cosmetic use.
  • the injection cosmetic product refers to a product that achieves a cosmetic effect by injecting a drug or a preparation; in an embodiment of the present invention, the injection is performed, for example, by intradermal injection or subcutaneous injection.
  • the invention proves that the xanthan gum has good biocompatibility, safety, high viscoelasticity and good gel formation when used for preparing cosmetic products; and its property is stable, and it is not easy to be degraded in the preparation process and in the human body, and no cross-linking is required. If injected into the skin, it can be stably stored for a long time without change and degradation, prolonging its action time.
  • xanthan gum solution is a typical pseudoplastic fluid, which has a very low viscosity at high shear rate, enabling it to It is easy to inject through a fine needle into the skin, and has a high viscosity and elasticity at a low shear rate, so that it can be injected into the skin to form a gel with certain emphasis, which can exist stably for a long time without migration or dispersion.
  • xanthan gum belongs to polysaccharides and has similar properties to polysaccharides such as chondroitin sulfate and hyaluronic acid, but xanthan gum is not easily degraded by enzymes and free radicals in the body, and has better stability.
  • the filling effect lasts for a long time and is superior to the existing similar products in the field of cosmetic filling.
  • xanthan gum can be stably stored for a long time without cross-linking, and avoids damage to human body caused by the use of cross-linking agent; compared with collagen products, xanthan gum is derived from microbial fermentation.
  • xanthan gum has the same advantages as collagen and cross-linked hyaluronic acid products, that is, it has the effect of timely shaping Immediately after the injection, the filling effect is maintained for a certain period of time, without multiple injections, which is more conducive to the physician to meet the patient's requirements for shaping the filling site.
  • the present invention uses xanthan gum as a main component for the preparation of a cosmetic product for the first time, and the results show that xanthan gum can increase the tissue volume and effectively reduce or eliminate skin wrinkles, fine lines, epidermal depressions and scars in a certain period of time, and achieve beauty. Or the purpose of shaping.
  • FIG. 5 Example 5 Histological observation of xanthan gum injection into the back of the guinea pig.
  • Figure 6 Example 8 Histological observation of xanthan gum injection into the back of the guinea pig head.
  • the embodiments of the present invention are described in detail below with reference to the embodiments of the present invention, but it is understood that the following examples are only intended to illustrate the invention and should not be construed as limiting the scope of the invention. If no specific conditions are specified in the examples, they are carried out according to the general conditions or the conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products that can be obtained commercially.
  • the xanthan gum is derived from the fermentation production of Xanthomonas oryzae var. chinensis, and the purified xanthan gum raw material obtained by purification and purification is prepared by reference method ( Han G, Wang Q Ling P, et al.
  • Xanthan gum (average molecular weight 5 million) 0.5 g
  • Hyaluronic acid 0.5g Sodium dihydrogen phosphate 0.16 g Disodium hydrogen phosphate 0.756 g Sodium chloride 0.411 g Water for injection to 100 mL pH 7.33 Osmotic pressure 300 mOsmol/L
  • Example 2 Injectable beauty product containing 2% xanthan gum
  • xanthan gum (average molecular weight 5 million) 2 g boric acid 1.166 g borax 0.114 g sodium chloride 0.220 g water for injection added to 100 mL pH 7.1 osmotic pressure 296 mOsmol / L
  • xanthan gum average molecular weight 5 million
  • boric acid 1.166 g borax 0.114 g sodium chloride 0.220 g water for injection added to 100 mL pH 7.1 osmotic pressure 296 mOsmol / L
  • Example 3 - 3% containing yellow Original rubber injection beauty products
  • Example 5 A painless injection cosmetic product containing 1% xanthan gum
  • Example 6 a painless injection cosmetic product containing 2% xanthan gum
  • Example 7 A painless injection cosmetic product containing 3% xanthan gum
  • Xanthan gum (average molecular weight 10 million) 3 g
  • Example 8 a painless injection cosmetic product containing 5% xanthan gum
  • Xanthan gum (average molecular weight 10 million) 5 g
  • Example 3 Based on the composition of Example 3 (all components except xanthan gum), a series of different concentrations of xanthan gum (1% ⁇ 5%) solution were prepared using a rotary rheometer ( Malvern Kinexus, England ) , 20mm flat plate, shear rate 0.1 s" 1 ⁇ 1000 s" 1 , different Concentration of xanthan gum solution! The ML changes with shear rate (see Figure 1).
  • the curve of the degree of xanthan gum solution as a function of shear rate exhibits the characteristics of a typical pseudoplastic fluid.
  • the xanthan gum solution has a very low viscosity at high shear rates, and the resistance when using a fine needle push is small and easy to inject.
  • the product of the embodiment of the invention has obvious viscoelasticity, and the elastic modulus G of the experimentally determined frequency range is always higher than the viscous modulus G", and a gel having a certain strength can be formed at a low shear rate. It has higher viscosity and elasticity.
  • the gel strength of Example 5 is weaker than that of crosslinked hyaluronic acid, and the gel strength of Example 7 is similar to that of crosslinked hyaluronic acid.
  • the strength of Example 8 is stronger than that of crosslinked hyaluronic acid. It shows that the xanthan gum injection beauty products with different viscoelasticity and strength can be provided by changing the product group, which can cover a wide range of products and can meet the market demand for different kinds of products.
  • control group injected with normal saline
  • group A injected with product of example 1
  • group B injected with product of example 2
  • Group C the product of Example 3 was injected.
  • After anesthesia prepare the skin and disinfect. A little point was taken on the left and right sides of the back of the rat, and the subcutaneous injection was performed at a dose of 0.5 ml and 0.25 ml, respectively.
  • the control group was injected with the same amount of normal saline at the same site.
  • Blood biochemical indicators include total cholesterol (TC), total protein (TP), albumin (ALB), urea nitrogen (BUN), total bilirubin (TBIL), creatinine (CR), triglycerides (TG), and blood glucose ( GLU), creatine phosphokinase (CK) and gamma-glutamyltransferase (GGT).
  • HE hematoxylin-eosin
  • Heart, brain, liver, spleen, lung, kidney and thymus were excised, weighed and stored in 4% formaldehyde solution, sectioned and histologically observed under light microscope.
  • Example 8 Female Hartley guinea pigs 40, weighed, anesthetized, prepared on the left and right sides of the regular back, disinfected. A total of 10 implantation sites were selected on the left and right sides of each guinea pig, and the enamel marks were drawn respectively. Among them, the xanthan gum product was injected at 6 points (the product of Example 5 was 2 points, and the product of Example 7 was 2 points. Example 8 product 2 points); Positive control 2 points, injection of commercially available cross-linked hyaluronic acid skin narrow filling agent (Run Baiyan, lot: 12021801, Huaxi Freda Biomedical Co., Ltd.); At 2 points, saline was injected. The injection sites of different samples were randomized. One and a half of the guinea pigs were injected intradermally with 0.05 ml per point, and the other half of the guinea pigs were injected subcutaneously with 0.2 ml per point.
  • the samples and adjacent tissues were taken as specimens, and stained with HE.
  • the morphology of the tissues around the injection site was observed under an optical microscope.
  • Example 5 was significantly reduced (clinical evaluation retention level 1), indicating that the product retention time was shorter when the xanthan gum content was lower; the implants of Examples 7 and 8 were still relatively complete, light touch It can be seen that there is no obvious degradation.
  • the degree of material retention is 3, 2, 4, 3, 4, 3, and 3, and the results of short-term and long-term animal experiments show that xanthan gum has good biocompatibility, no obvious inflammatory reaction, and is non-toxic to animal organs.
  • a safe injection of cosmetic filling material The xanthan gum injection beauty product can be stably stored in the skin for a long time, and the skin filling effect is obvious.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une utilisation de gomme de xanthane dans la préparation de produits de beauté injectables pour combler des rides, des ridules, le relâchement cutané et/ou des cicatrices, et un produit de beauté injectable contenant de la gomme xanthane utilisé pour le comblement de rides, de ridules, du relâchement cutané et/ou de cicatrices.
PCT/CN2013/077374 2013-06-18 2013-06-18 Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables WO2014201618A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201380077303.7A CN105338988B (zh) 2013-06-18 2013-06-18 黄原胶在制备注射美容产品中的用途
PCT/CN2013/077374 WO2014201618A1 (fr) 2013-06-18 2013-06-18 Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/077374 WO2014201618A1 (fr) 2013-06-18 2013-06-18 Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables

Publications (1)

Publication Number Publication Date
WO2014201618A1 true WO2014201618A1 (fr) 2014-12-24

Family

ID=52103791

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2013/077374 WO2014201618A1 (fr) 2013-06-18 2013-06-18 Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables

Country Status (2)

Country Link
CN (1) CN105338988B (fr)
WO (1) WO2014201618A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019011603A (es) * 2017-03-26 2021-08-16 Robyn Vivi Stafford Metodo de tratamiento de las condiciones de la piel de los parpados.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741825A (zh) * 2003-01-27 2006-03-01 Abr发明公司 基于陶瓷的用来注入软组织的可注射植入物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101658692A (zh) * 2008-08-27 2010-03-03 山东省生物药物研究院 一种结冷胶组合物及其制备方法和用途
CN101940587B (zh) * 2009-07-03 2012-07-18 山东省生物药物研究院 一种含有黄原胶的关节腔内注射用药物制剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1741825A (zh) * 2003-01-27 2006-03-01 Abr发明公司 基于陶瓷的用来注入软组织的可注射植入物

Also Published As

Publication number Publication date
CN105338988B (zh) 2019-05-14
CN105338988A (zh) 2016-02-17

Similar Documents

Publication Publication Date Title
JP6995946B2 (ja) 抗酸化物質を含む皮膚充填剤組成物
Fakhari et al. Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment
RU2712641C2 (ru) Дермальный филлер на основе поперечносшитой гиалуроновой кислоты и карбоксиметилцеллюлозы в качестве лубриканта
US8455465B2 (en) Heat sterilised injectable composition of hyaluronic acid or one of the salts thereof, polyols and lidocaine
KR102161861B1 (ko) 잔주름 치료를 위한 진피 필러 조성물
RU2648450C2 (ru) Приемлемая для инъекций стерильная водная композиция на основе сшитой гиалуроновой кислоты и гидроксиапатита для применения в пластической хирургии
KR102265076B1 (ko) 진피 필러 조성물
TW201718035A (zh) 原位可交聯的多醣組合物及其用途
EP3125961B1 (fr) Produits de comblement de tissu mou à base de polysaccharide, à persistance améliorée
JP2014237719A (ja) 麻酔剤を含有するヒアルロン酸系ゲル
CN104086788A (zh) 一种注射用修饰透明质酸钠凝胶
CN107522881B (zh) 制备单相修饰透明质酸钠凝胶的方法
US20180147320A1 (en) Injectable Homogeneous Aqueous Solution of Chitosan Having a pH Close to the Physiological pH
US20200179419A1 (en) Method for the manufacture and use of a bionic hydrogel composition for medical applications
CN105451786A (zh) 交联的透明质酸、用于其制备的工艺及其在美学领域中的用途
ES2871020T3 (es) Quitosano con carga aniónica
WO2014201618A1 (fr) Utilisation de gomme de xanthane dans la préparation de produits de beauté injectables
CN109843345A (zh) 作用于脂肪细胞的新型组合物
RU2750000C1 (ru) Способ получения модифицированного гиалуронана и его применение в медицине, в том числе при эндопротезировании
TW202042848A (zh) 用以填充組織的美容方法及聚葡萄胺糖溶液於製造外科手術之治療方法用之組成物的用途
CA3208406A1 (fr) Produits implantables ou injectables a base de polymeres et leur procede de preparation
CN116831943A (zh) 一种注射用复合透明质酸钠溶液及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380077303.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13887231

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 13887231

Country of ref document: EP

Kind code of ref document: A1